Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors at 2 institutions in 1 country.
Sarah van TolDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0002-9905-920X
Adam HageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0001-7668-892X
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0002-5058-5444
Alexander N FreibergInstitute for Human Infections and Immunity, Sealy & Smith Foundation, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0001-8413-8960
The University of Texas Medical Branch at Galveston · USRutgers, The State University of New Jersey · US
Funding
Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus DiseaseP01AI150585 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, GARCIA-BLANCO, MARIANO A. · 2021 to 2025
$11.3M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
The Role of the Host Ubiquitin System in Promoting SARS-CoV-2 Replication and PathogenesisR01AI166668 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2021 to 2025
$2.6M
The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced PathologyR01AI155466 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Ricardo Rajsbaum · 2021 to 2026
$2.5M
Therapeutic efficacy of favipiravir against henipavirus infectionsR21AI164401 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FREIBERG, ALEXANDER NICLAS · 2021 to 2022
$440k
Microphysiologic human organ cultures to study Nipah virus-induced lung pathologyR21AI138233 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FREIBERG, ALEXANDER NICLAS · 2018 to 2019
$434k
Roles of Pteropine Bat and Human TRIMs in Regulating Henipavirus InfectionF31AI152422 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI VAN TOL, SARAH · 2021 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.